DEVELOPMENT OF A NOVEL BIOARTIFICIAL LIVER

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$177,936.00
Award Year:
2002
Program:
SBIR
Phase:
Phase I
Contract:
1R43DK061076-01
Agency Tracking Number:
DK061076
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
ARBIOS TECHNOLOGIES, INC.
ARBIOS TECHNOLOGIES, INC., 2331 BUCKINGHAM LN, LOS ANGELES, CA, 90077
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JACEK ROZGA
(310) 423-7702
JACEK.ROZGA@CSHS.ORG
Business Contact:
JACEK ROZGA
(310) 877-8496
JROZGA@EARTHLINK.NET
Research Institution:
n/a
Abstract
ARBIOS developed a novel hybrid bioartificial live r(HyBAL) to treat patients with liver failure of various etiologies. In the absence of any other alternative, such patients must receive a liver transplant or endure prolonged hospitalization. In treating acute liver failure it is critical to provide whole liver functions. It is believed that liver support at this level of complexity requires utilization of viable isolated liver cells. Our own argument, which dates back to the development of our first-generate bioartificial liver, is that a truly effective system should be a hybrid one, i.e., it should combine liver cell therapy and detoxification using sorbents (e.g., activated charcoal, exchange resin). The HYBAL is the first liver assist system in which these two functions are integrated in a single molecule. Depending on the cause of liver disease, severity of illness and deficiency of specific liver functions, these modes of therapy can be provided individually, simultaneously or sequentially. In addition, the HYBAL's basic commercially available kidney dialysis platform represents a major improvement in efficiency with a concomitant reduction in cost and complexity compared to other existing systems. The goal of this proposal is to validate the HyBAL concept. The prototype HyBAL devices will utilize matrix-anchored rat or pig hepatocytes and sorbents (charcoal and exchange resin particles). They will e perfused for 8 hours with plasma removed with pigs with surgically-induced fulminant hepatic failure(FHF). Changes in plasma levels of ammonia, urea, bilirubin and other liver-specific parameters will be monitored. In addition, the HyBAL will be challenged with exogenous ammonium chloride, galactose and lidocaine. In vivo, he ability of HyBAL to support pigs with FHF will be examined. In both experimental settings, HyBAL devices from which either cell therapy or sorbents have been omitted, will be tested to determine the respective role of cell and sorption therapy in the overall HyBAL performance.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government